This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Best Biotech Stocks to Buy Now as AI Stocks Tank: ARGX
by Benjamin Rains
Investors should consider buying resurgent healthcare and biotech stocks amid the AI selloff. Today, we are digging into why it might be time to buy biopharmaceutical stock Argenx (ARGX).
XLVPositive Net Change XBINegative Net Change ARGXPositive Net Change
artificial-intelligence biotechnology biotechs pharmaceuticals
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
by Ekta Bagri
Four biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.
TGTXPositive Net Change RGNXNegative Net Change IMNMNegative Net Change PMNNegative Net Change BMYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
NVO Q3 Earnings Beat Estimates on Wegovy Pill Growth, Outlook Raised
by Zacks Equity Research
Novo beats Q3 earnings and revenue estimates as Wegovy pill sales surge, driving a higher 2026 outlook despite diabetes weakness and pricing pressures.
NVONegative Net Change TGTXPositive Net Change IOVANegative Net Change IBRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
AMGN Stock Down Despite Q3 Earnings & Sales Beat, Raised Guidance
by Zacks Equity Research
Amgen shares fall despite Q3 earnings and revenue beats. Steep declines in Prolia and Xgeva offset strong growth across key drug portfolios and raised 2026 guidance.
AMGNNo Net Change AZNNegative Net Change NVONegative Net Change LLYPositive Net Change
biotechs earnings pharmaceuticals
NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View
by Zacks Equity Research
Neurocrine Biosciences beats Q3 earnings and revenue estimates as strong Ingrezza demand, Crenessity growth and higher 2026 sales guidance drive momentum.
NBIXPositive Net Change TGTXPositive Net Change AMRXPositive Net Change
biotechs earnings medical
JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View
by Zacks Equity Research
Jazz Pharmaceuticals beat Q3 2026 revenue and earnings estimates, driven by oncology and rare sleep growth, and raises its full-year sales outlook.
JAZZPositive Net Change TGTXPositive Net Change AMRXPositive Net Change
biotechs cannabis medical
Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues
by Zacks Equity Research
RXRX Q3 revenues surge 258.5%, beating estimates as a $10 million Sanofi milestone payment boosts results and advances its drug pipeline.
RXRXNegative Net Change SNYPositive Net Change IOVANegative Net Change AMRXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised
by Zacks Equity Research
Vertex misses Q3 earnings estimates but beats revenue expectations, driven by CF drug sales and growth in Casgevy and Journavx, prompting a 2026 sales outlook hike.
VRTXNegative Net Change TGTXPositive Net Change CRSPNegative Net Change
biotechs earnings
Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
VTRS heads into Q3 earnings with new product growth, regional sales trends and supply challenges shaping its outlook.
VTRSPositive Net Change TGTXPositive Net Change ACADPositive Net Change IOVANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts?
by Zacks Equity Research
AMGN, PFE, MRNA, NVO and VTRS are set to report this week as recent beats and key drug demand set up a pivotal Q3 earnings test for pharma giants.
PFEPositive Net Change NVONegative Net Change AMGNNo Net Change MRNANegative Net Change VTRSPositive Net Change
biotechs pharmaceuticals